CYP 1.89% 27.0¢ cynata therapeutics limited

Ann: Cynata Expands trial in COVID-19 & Respiratory Failure, page-174

  1. 6,922 Posts.
    lightbulb Created with Sketch. 1282
    This is from last year's annual report 14th Oct 2021 - less than 12 months ago!!!:


    "Enrolment and patient treatment commenced in
    MEND respiratory failure trial
    Following commencement in August 2020, Cynata
    received ethics committee approval in March 2021
    to expand the recruitment criteria of the MEND
    (MEseNchymal coviD-19) clinical trial to include
    patients admitted to an ICU with respiratory failure of
    any cause. The expansion is expected to accelerate
    recruitment into the trial by increasing the pool of
    eligible patients with COVID-19 no longer a limiting
    requirement for eligibility.
    Cynata achieved a significant milestone by treating
    the first patient in the trial in May 2021. The openlabel randomised controlled clinical trial design aims
    to investigate the safety and early efficacy of Cymerus
    MSCs in 24 adult patients with respiratory failure.
    The trial will involve 12 critically infected patients
    randomised to receive Cymerus MSC infusions, in
    addition to standard of care, and 12 patients who will
    be randomised to the control group and will receive
    current standard of care only. Given the seasonal
    nature of the incidence of respiratory distress and the
    highly uncertain situation around COVID-19 outbreaks
    in Australia at present, Cynata is currently unable to
    provide firm guidance on when trial results might be
    expected. However, it is currently estimated that the
    trial will complete late in calendar 2021. The trial is
    fully funded by Cynata’s existing cash reserves.
    Cynata has identified acute respiratory distress
    syndrome (ARDS), sepsis, and cytokine release
    syndrome (CRS) as targets relevant to the outcome
    of this trial, as they present significant unmet medical
    needs, and are manifestations of the excessive
    inflammatory responses typically seen in acutely


    Then the trial was expanded further to include more hospitals. Then it was abandoned.

    You couldn't get 24 patients after all that???

    24???!!!!

    There is more than 24 in the ICU's across Australia for Covid 19 right now!!!





    Why don't the shareholders want to know more????


 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
27.0¢
Change
0.005(1.89%)
Mkt cap ! $48.50M
Open High Low Value Volume
27.0¢ 27.0¢ 27.0¢ $4 13

Buyers (Bids)

No. Vol. Price($)
1 18895 26.5¢
 

Sellers (Offers)

Price($) Vol. No.
28.5¢ 5700 1
View Market Depth
Last trade - 13.43pm 05/07/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.